We are live on
!
Find out more
EI
EAM Investors Portfolio holdings
AUM
$866M
1-Year Est. Return
377.14%
This Fund
S&P 500
This Quarter
Est. Return
+27.4%
1 Year Est. Return
+377.14%
3 Year Est. Return
+5,228.32%
5 Year Est. Return
+49,813.17%
10 Year Est. Return
+19,957,666.26%
AUM
$409M
AUM Growth
+$1.31M
(+0.32%)
Cap. Flow
-$55.4M
Cap. Flow
% of AUM
-13.56%
Top 10 Holdings %
Top 10 Hldgs %
9.96%
Holding
345
New
97
Increased
17
Reduced
117
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Upbound Group
UPBD
|
+$2.54M |
| 2 |
PRFT
Perficient Inc
PRFT
|
+$2.53M |
| 3 |
ARQL
Arqule Inc
ARQL
|
+$2.33M |
| 4 |
Goosehead Insurance
GSHD
|
+$2.32M |
| 5 |
CryoPort
CYRX
|
+$2.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TEUM
Pareteum Corporation
TEUM
|
+$3.8M |
| 2 |
NVTA
Invitae Corporation
NVTA
|
+$3.69M |
| 3 |
Adeia
ADEA
|
+$3.05M |
| 4 |
American Superconductor
AMSC
|
+$3.05M |
| 5 |
Stride
LRN
|
+$2.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.79% |
| 2 | Technology | 25.64% |
| 3 | Industrials | 15.05% |
| 4 | Consumer Discretionary | 9.18% |
| 5 | Financials | 5.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PRVB
226
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $710K | 0.17% |
+58,693
| New | +$319K |
|
227
Veritone
VERI
$101M
| $705K | 0.17% |
+84,275
| New | +$626K |
|
|
PFNX
228
DELISTED
Pfenex Inc.
PFNX
| $688K | 0.17% |
+102,061
| New | +$652K |
|
229
Intellicheck
IDN
$73.1M
| $687K | 0.17% |
+118,599
| New | +$508K |
|
|
LUNA
230
DELISTED
Luna Innovations Incorporated
LUNA
| $686K | 0.17% |
152,389
-619
| -0.4% | -$2.65K |
|
|
SOLY
231
DELISTED
Soliton, Inc.
SOLY
| $682K | 0.17% |
46,403
+5,677
| +14% | +$73.3K |
|
|
QUMU
232
DELISTED
Qumu Corp.
QUMU
| $660K | 0.16% |
+159,088
| New | +$536K |
|
|
CTHR
233
DELISTED
Charles & Colvard Ltd
CTHR
| $618K | 0.15% |
+39,110
| New | +$593K |
|
234
Avalo Therapeutics
AVTX
$965M
| $605K | 0.15% |
39
| – | – |
|
|
ENZ
235
DELISTED
Enzo Biochem, Inc.
ENZ
| $603K | 0.15% |
+178,939
| New | +$630K |
|
|
AKTS
236
DELISTED
Akoustis Technologies Inc
AKTS
| $542K | 0.13% |
+84,653
| New | +$579K |
|
|
SHSP
237
DELISTED
SharpSpring, Inc.
SHSP
| $533K | 0.13% |
40,999
-28,369
| -41% | -$475K |
|
|
IEC
238
DELISTED
IEC Electronics Corp.
IEC
| $517K | 0.13% |
82,281
-41,436
| -33% | -$274K |
|
|
ATXI
239
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
| $474K | 0.12% |
67
-15
| -18% | -$86.8K |
|
|
HYGS
240
DELISTED
Hydrogenics Corp
HYGS
| $474K | 0.12% |
+31,923
| New | +$315K |
|
241
XBiotech
XBIT
$68M
| $465K | 0.11% |
61,327
-29,023
| -32% | -$252K |
|
242
ANI Pharmaceuticals
ANIP
$1.8B
| $270K | 0.07% |
+3,287
| New | +$234K |
|
243
Arbor Realty Trust
ABR
$964M
| – | – |
-97,027
| Closed | -$1.26M |
|
244
ACI Worldwide
ACIW
$5.83B
| – | – |
-55,713
| Closed | -$1.83M |
|
245
Agree Realty
ADC
$9.34B
| – | – |
-23,234
| Closed | -$1.61M |
|
|
246
Adeia
ADEA
$2.94B
| – | – |
-493,252
| Closed | -$3.05M |
|
247
AudioEye
AEYE
$72.3M
| – | – |
-74,431
| Closed | -$671K |
|
|
AFMD
248
DELISTED
Affimed
AFMD
| – | – |
-13,457
| Closed | -$565K |
|
249
Allot
ALLT
$372M
| – | – |
-123,485
| Closed | -$980K |
|
250
Alarm.com
ALRM
$2.71B
| – | – |
-26,619
| Closed | -$1.73M |
|
Similar funds
NEPWA
RWM
MCM
HP
OMG
RB
BGC
ICCFIA
EAM Investors's Q2 2019 Portfolio in Review
As of Q2 2019, EAM Investors held 345 positions worth $409M, up 0.32% from $408M the previous quarter. Its ten largest holdings account for 10% of the portfolio.
EAM Investors withdrew a net $55.4M in Q2 2019, closing 103 positions and reducing 117 holdings. Its most notable exit was Pareteum Corporation, an estimated $3.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 28% a quarter earlier, followed by Technology and Industrials.
Against the trend, EAM Investors opened a new position in Upbound Group worth $2.85M.
- EAM Investors's largest Q2 2019 buy was Upbound Group: 106,882 shares worth $2.85M.
- EAM Investors added most to Krystal Biotech in Q2 2019, an estimated $1.92M increase.
- EAM Investors's biggest Q2 2019 reduction was Codexis, cutting an estimated $2.65M.
- EAM Investors fully exited Pareteum Corporation in Q2 2019, selling an estimated $3.8M.
- EAM Investors's ten largest holdings make up 10% of its $409M portfolio in Q2 2019.
- EAM Investors opened 97 new positions and closed 103 in Q2 2019.
- EAM Investors's portfolio value rose 0.32% quarter-over-quarter to $409M.
Based on EAM Investors's 13F filing for Q2 2019, filed 14 Aug 2019.